Characteristic | Frequency (%) | No. of DDIs Median [Q1-Q3] | P-value |
---|---|---|---|
Age | < 0.001 a | ||
≤ 50 | 127(38.8%) | 3.0 (1.0–5.0) | |
> 50 | 200 (61.2%) | 4.0 (2.0–8.0) | |
Gender | 0.792 a | ||
Male | 103(31.5%) | 3.0 (2.0–7.0) | |
Female | 224 (68.5%) | 3.0 (1.0–7.0) | |
BMI | 0.242 b | ||
< 18.5 | 7 (2.1%) | 2.0 (2.0–4.0) | |
18.5–24.9 | 83 (25.4%) | 3.0 (1.0–6.0) | |
25–29.9 | 119 (36.4%) | 4.0 (2.0–7.0) | |
≥ 30 | 118 (36.1%) | 4.0 (2.0–7.0) | |
Cancer type | 0.389 a | ||
Hematological | 83 (25.4%) | 3.0 (2.0–5.0) | |
Solid | 244 (74.6%) | 4.0 (1.0–7.0) | |
Metastasis | 0.304 a | ||
No | 195 (59.6%) | 4.0 (2.0–7.0) | |
Yes | 132 (40.4%) | 3.0 (1.0–7.0) | |
Palliative | 0.106 a | ||
No | 200 (61.2%) | 4.0(2.0–7.0) | |
Yes | 127 (38.8%) | 3.0 (1.0–6.0) | |
Duration of treatment | 0.001 b | ||
< 1 | 193 (59.0%) | 4.0 (2.0–7.0) | |
1–3 | 90 (27.5%) | 3.0 (1.0–6.0) | |
> 3 | 44(13.5%) | 2.0 (1.0–4.8) | |
Number of comorbid diseases | < 0.001 b | ||
0 | 165 (50.5) | 1.0 (1.0–2.0) | |
1 | 91 (27.8) | 2.0 (1.0–4.0) | |
≥ 2 | 71 (21.7) | 4.0 (3.0–4.0) | |
All drugs used | < 0.001 a | ||
≤ 7 | 158 (48.3%) | 2.0 (1.0–3.0) | |
> 7 | 169(51.7%) | 5.0 (3.0–10.0) | |
Anticancer treatment | 0.001 a | ||
≤ 2 | 200 (61.2%) | 3.0 (1.0–5.8) | |
> 2 | 127 (38.8%) | 5.0 (2.0–8.0) | |
Education | 0.314 b | ||
Not educated | 18 (5.5%) | 6.0 (2.5–9.0) | |
Standard < 5 | 32 (9.8%) | 3.0 (0.0–7.0) | |
Standard 5–10 | 105(32.1%) | 3.0 (2.0–6.5) | |
Standard 11–12 | 100 (30.6%) | 3.0 (1.0–7.0) | |
University qualification | 72 (22.0%) | 3.0 (1.0–6.0) |